Trial Profile
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Opaganib (Primary) ; Opaganib (Primary)
- Indications COVID-19 pneumonia
- Focus Registrational; Therapeutic Use
- Sponsors RedHill Biopharma
- 01 May 2023 According to a RedHill Biopharma media release, data from the opaganib global Phase 2/3 study has been submitted for peer review
- 19 Oct 2022 According to a RedHill Biopharma media release, post hoc (N=251) analysis presented in a RedHill Biopharma media release.
- 26 Aug 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.